Member Info for L0ngterm

I think a good example of what is being discussed. I Think the timeline was jan-Oct from partner to buyout. 355 million paid in 2001 by Abbott. All food for thought

https://www.google.co.uk/amp/s/www.chicagotribune.com/news/ct-xpm-2001-04-06-0104060114-story,amp.html

https://www.genomeweb.com/archive/abbott-acquire-vysis-355m#.YCZb92TfXYU

Not so sure, it could gap up quickly given the correct conditions. That maybe this months fda update, or possible any news/progress on chronocort

Courtesy of the other bb.. some New broker research

https://www.calvinepartners.com/research

Also worth noting that DNL have shares in ETON which was part of the deal, Which have almost doubled in value. Eton Are estimating the market size being 100 million, where diurnal have it at 30 million for akindl. On Etons trading update they were very, very positive on FDA approval and plan executing sales almost immediately.

Basically a major shareholder has been reducing there holding ( Richard Griffith’s). Beyond that, some may say this is a boring share, and by boring and this is purely IMHO, the company has successfully mapped out and delivered thus far on its pipeline for this year,. it’s is not chasing 10 billlion dollar markets, shiny objects etc. The biggest question is the direction the company is taking and will progress with chronocort, if successful with progress and European approval this should look significantly different.

The platform I was looking at for trades volumes was reporting a lot more sells. I suppose time will tell.

W. Health LP seem to be the only large shareholder (54 million shares), that could sell this volume. Will be curious to see where they went. If it is them then that is roughly half of there holding sold. Hopefully the RNS Will clarify

thanks for taking the time to post this here. Greatly appreciated.

All markets are down, FTSE is roughly 2200 points down from its 52wk high. At least here it seems to be smaller volumes bringing the price down.

A lawyer would, I agree,. I would also assume a lawyer would also check any published materials with this information within it. If not Edison’s lawyers I would imagine, would Double check Content before publishing..

On new information, I thought I read a post stating patent impacting the core product (not exclusivity period).

That’s not what the company has communicated so far, Basically they have stated the impact as trivial and would reduce the exclusivity, evidenced in the Edison investor research notes etc. Hence I was wondering where this new information has come from?

Hi,

Can you point me to where it details the patent challenge impacts the core product? As previously the discussion has been related to the manufacturing of the product, and would reduce the duration of exclusivity I.e. when generics can be produced.

Link: https://www.ncbi.nlm.nih.gov/m/pubmed/28843267/

“CONCLUSIONS: CTC screening provided a highly sensitive biomarker for the early detection of cancer, with higher CTC counts being associated with higher risk of malignancy. CTC monitoring over time indicated treatment effectiveness. Nutrients with anti-carcinogenic properties could reduce CTC count, and included curcumin, garlic, green tea, grape seed, modified citrus pectin, and medicinal mushroom extract.”